Eltrombopag (Revolade) is an oral thrombopoietin receptor agonist that plays an important role in the treatment of various hematological disorders.

How Effective is Eltrombopag (Revolade) in Treatment?

Efficacy in Chronic Immune Thrombocytopenia (ITP)

Eltrombopag can significantly increase the platelet count in patients with chronic ITP and reduce the risk of bleeding.

Clinical studies have shown that this drug can maintain platelets at a safe level and reduce the occurrence of bleeding events.

Efficacy in Chronic Hepatitis C-Related Thrombocytopenia

For patients with chronic hepatitis C who need to receive interferon therapy, eltrombopag can effectively correct thrombocytopenia, allowing patients to initiate and maintain antiviral treatment.

Indicated Populations for Eltrombopag (Revolade)

Patients with Chronic ITP

Indicated for children aged 1 year and above and adults with chronic ITP who have an inadequate response to glucocorticoids, immunoglobulins, or splenectomy.

Particularly indicated for patients whose degree of thrombocytopenia and clinical status increase the risk of bleeding.

Patients with Chronic Hepatitis C

Indicated for patients with chronic hepatitis C who cannot initiate or maintain interferon therapy due to thrombocytopenia.

Patients with Severe Aplastic Anemia

Indicated for patients with severe aplastic anemia who have an inadequate response to immunosuppressive therapy.

For East Asian patients or those with liver injury, the initial dose needs to be adjusted.

Medication Use in Special Populations

Pregnant women: The benefits and risks must be weighed when using this drug. Lactating women should decide whether to discontinue the drug or stop breastfeeding.

Elderly patients: No dose adjustment is required, but close monitoring is necessary.

Patients with hepatic impairment: Dose reduction is required; no dose adjustment is needed for patients with renal impairment.

East Asian patients: Dose adjustment is also required due to metabolic differences.

Medication Monitoring for Eltrombopag (Revolade)

Pre-Treatment Assessment

Conduct a comprehensive assessment of liver function (ALT, AST, bilirubin).

Perform a baseline ophthalmological examination (to assess the risk of cataracts).

Document a detailed medication history (with special attention to drugs containing polyvalent cations).

Hematological Monitoring

ITP patients: Monitor platelet count weekly initially, and monthly after the condition stabilizes.

Hepatitis C patients: Monitor platelet count weekly during antiviral therapy.

Aplastic anemia patients: Regularly assess the complete blood cell count (counts of three lineages of blood cells).

Liver Function Monitoring

Monitor liver function every 2 weeks during the dose adjustment period.

Monitor liver function monthly after reaching a stable dose.

If abnormal liver enzymes occur, the frequency of monitoring needs to be increased.